{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-22-000028","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2022-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.811948+00:00","generated_at":"2026-06-23T01:31:11.812225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance","bullets":["Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).","GAAP diluted EPS $7.84; Non-GAAP diluted EPS $4.77.","Lecanemab Phase 3 Clarity AD met primary endpoint and all key secondary endpoints in early Alzheimer's.","Tofersen NDA accepted with priority review; PDUFA date April 25, 2023.","Company raises full year 2022 financial guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-22-000028","json":"https://secwatch.observer/filing/0000875045-22-000028.json","markdown":"https://secwatch.observer/filing/0000875045-22-000028.md","text":"https://secwatch.observer/filing/0000875045-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/0000875045-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/biib-20221025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:31:11.812225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}